Letter by Tampaki et al Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Author: Tampaki, Ekaterini Christina MD, PhD, PharmD; Tampakis, Athanasios MD; Pantos, Costas MD, PhD

Page: 982-983

http://ift.tt/2F86Y2C